FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2802617131> ?p ?o ?g. }

• W2802617131 endingPage "1829" @default.
• W2802617131 startingPage "1821" @default.
• W2802617131 abstract "Aims To characterize the pharmacokinetics, pharmacodynamics and safety of esaxerenone, a mineralocorticoid receptor antagonist, in healthy adult Japanese men. Methods Double‐blind, placebo‐controlled, sequential, dose‐escalation studies were conducted in subjects randomized to receive oral once‐daily esaxerenone (ranges: 5–200 mg [single‐dose]; 10–100 mg over 10 days [multiple‐dose]) or placebo under fasting conditions. Plasma concentrations were analysed by liquid chromatograph–tandem mass spectrometry. Pharmacokinetic parameters were determined by noncompartment analysis. Plasma/urine levels of pharmacodynamic biomarkers for mineralocorticoid receptor activity were evaluated. Results In total, 48/48 and 39/40 subjects completed the single‐ and multiple‐dose studies, respectively. Exposures were generally dose‐proportional. The t max , t 1/2 and CL/F remained unchanged, independent of dose; the respective ranges were 1.5–4.0 h, 22.3–25.1 h, and 4.0–5.2 l h –1 (multiple‐dose study). V z /F ranged from 136.5 to 283.7 l in the multiple‐dose study, and exposure reached steady state by day 4. The mean observed accumulation ratio, by dose, ranged from 1.36–1.98. The urinary Na + /K + ratio increased after single‐dose administration; however, its relationship to the doses tested remains unclear. Plasma renin activity, active renin concentration and aldosterone concentration increased dose‐dependently. Although blood potassium levels increased dose‐dependently in the multiple‐dose study (reaching a maximum mean ± standard deviation of 4.63 ± 0.354 mmol l –1 in the 100‐mg group), no safety/tolerability‐related problems were detected in either study. Conclusions Exposure levels in healthy adults receiving esaxerenone were generally dose‐proportional. Dose‐dependent changes in plasma pharmacodynamic biomarkers for the mineralocorticoid receptor were identified during multiple‐dose treatment and support the pharmacological activity of esaxerenone. No important safety concerns were identified." @default.
• W2802617131 created "2018-05-17" @default.
• W2802617131 creator A5005942636 @default.
• W2802617131 creator A5032014188 @default.
• W2802617131 creator A5055533000 @default.
• W2802617131 creator A5060920018 @default.
• W2802617131 creator A5068428660 @default.
• W2802617131 creator A5070125013 @default.
• W2802617131 date "2018-06-07" @default.
• W2802617131 modified "2023-10-10" @default.
• W2802617131 title "Single‐ and multiple‐dose escalation study to assess pharmacokinetics, pharmacodynamics and safety of oral esaxerenone in healthy Japanese subjects" @default.
• W2802617131 cites W1971136179 @default.
• W2802617131 cites W1975196657 @default.
• W2802617131 cites W2047103814 @default.
• W2802617131 cites W2125226019 @default.
• W2802617131 cites W2137073289 @default.
• W2802617131 cites W2152094259 @default.
• W2802617131 cites W2164705414 @default.
• W2802617131 cites W2174401463 @default.
• W2802617131 cites W2535176244 @default.
• W2802617131 cites W2602037410 @default.
• W2802617131 cites W2765684626 @default.
• W2802617131 cites W2766306821 @default.
• W2802617131 cites W2767077155 @default.
• W2802617131 cites W2769696378 @default.
• W2802617131 cites W2771328536 @default.
• W2802617131 cites W2917732217 @default.
• W2802617131 cites W642118772 @default.
• W2802617131 doi "https://doi.org/10.1111/bcp.13616" @default.
• W2802617131 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6046505" @default.
• W2802617131 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29688582" @default.
• W2802617131 hasPublicationYear "2018" @default.
• W2802617131 type Work @default.
• W2802617131 sameAs 2802617131 @default.
• W2802617131 citedByCount "41" @default.
• W2802617131 countsByYear W28026171312018 @default.
• W2802617131 countsByYear W28026171312019 @default.
• W2802617131 countsByYear W28026171312020 @default.
• W2802617131 countsByYear W28026171312021 @default.
• W2802617131 countsByYear W28026171312022 @default.
• W2802617131 countsByYear W28026171312023 @default.
• W2802617131 crossrefType "journal-article" @default.
• W2802617131 hasAuthorship W2802617131A5005942636 @default.
• W2802617131 hasAuthorship W2802617131A5032014188 @default.
• W2802617131 hasAuthorship W2802617131A5055533000 @default.
• W2802617131 hasAuthorship W2802617131A5060920018 @default.
• W2802617131 hasAuthorship W2802617131A5068428660 @default.
• W2802617131 hasAuthorship W2802617131A5070125013 @default.
• W2802617131 hasBestOaLocation W28026171311 @default.
• W2802617131 hasConcept C111113717 @default.
• W2802617131 hasConcept C112705442 @default.
• W2802617131 hasConcept C126322002 @default.
• W2802617131 hasConcept C134018914 @default.
• W2802617131 hasConcept C138976137 @default.
• W2802617131 hasConcept C142724271 @default.
• W2802617131 hasConcept C197934379 @default.
• W2802617131 hasConcept C198710026 @default.
• W2802617131 hasConcept C204787440 @default.
• W2802617131 hasConcept C27081682 @default.
• W2802617131 hasConcept C2776069600 @default.
• W2802617131 hasConcept C2778375690 @default.
• W2802617131 hasConcept C2778525890 @default.
• W2802617131 hasConcept C2780026642 @default.
• W2802617131 hasConcept C71924100 @default.
• W2802617131 hasConcept C79410662 @default.
• W2802617131 hasConcept C84393581 @default.
• W2802617131 hasConcept C98274493 @default.
• W2802617131 hasConceptScore W2802617131C111113717 @default.
• W2802617131 hasConceptScore W2802617131C112705442 @default.
• W2802617131 hasConceptScore W2802617131C126322002 @default.
• W2802617131 hasConceptScore W2802617131C134018914 @default.
• W2802617131 hasConceptScore W2802617131C138976137 @default.
• W2802617131 hasConceptScore W2802617131C142724271 @default.
• W2802617131 hasConceptScore W2802617131C197934379 @default.
• W2802617131 hasConceptScore W2802617131C198710026 @default.
• W2802617131 hasConceptScore W2802617131C204787440 @default.
• W2802617131 hasConceptScore W2802617131C27081682 @default.
• W2802617131 hasConceptScore W2802617131C2776069600 @default.
• W2802617131 hasConceptScore W2802617131C2778375690 @default.
• W2802617131 hasConceptScore W2802617131C2778525890 @default.
• W2802617131 hasConceptScore W2802617131C2780026642 @default.
• W2802617131 hasConceptScore W2802617131C71924100 @default.
• W2802617131 hasConceptScore W2802617131C79410662 @default.
• W2802617131 hasConceptScore W2802617131C84393581 @default.
• W2802617131 hasConceptScore W2802617131C98274493 @default.
• W2802617131 hasIssue "8" @default.
• W2802617131 hasLocation W28026171311 @default.
• W2802617131 hasLocation W28026171312 @default.
• W2802617131 hasLocation W28026171313 @default.
• W2802617131 hasOpenAccess W2802617131 @default.
• W2802617131 hasPrimaryLocation W28026171311 @default.
• W2802617131 hasRelatedWork W146935509 @default.
• W2802617131 hasRelatedWork W2017221000 @default.
• W2802617131 hasRelatedWork W2076569737 @default.
• W2802617131 hasRelatedWork W2081491491 @default.
• W2802617131 hasRelatedWork W2143300626 @default.
• W2802617131 hasRelatedWork W2150739221 @default.
• W2802617131 hasRelatedWork W2156614560 @default.

• next